{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:18Z","timestamp":1792784898264,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":112,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd.","id":[{"id":"https:\/\/ror.org\/01v743b94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The JBCRG-C08\/ATTRIBUTE (UMIN000041747) study assessed atezolizumab plus nab-paclitaxel\u2019s safety and effectiveness in a metastatic triple-negative breast cancer population, including IMpassion130-ineligible patients. The primary outcome was incidence of investigator-assessed adverse events (AEs). Safety and full analysis populations included 149 and 148 patients, respectively; 4.0% of the full analysis population had Eastern Cooperative Oncology Group performance status \u22652 and 7.4% had a history\/comorbidity of autoimmune disease (AID) at baseline. AEs occurred in 96.6% of the safety analysis population; serious AEs (SAEs), in 16.8%; and immune-related AEs (irAEs), in 30.9%. irAE incidence was 45.5% in patients with a history\/comorbidity of AID. Notable SAEs included pneumonitis (3.4%), diarrhoea, pyrexia, adrenal insufficiency and cardiac failure (1.3% each). Two cases of Grade 5 pneumonitis occurred. Regarding effectiveness, median progression-free survival was 5.6 months (95% confidence interval, 4.2\u20136.7). This first analysis found no new safety concerns with atezolizumab combination therapy, although patients with AID require careful monitoring.<\/jats:p>","DOI":"10.1038\/s41523-026-00997-y","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:04:32Z","timestamp":1782507872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08\/ATTRIBUTE"],"prefix":"10.1038","volume":"12","author":[{"given":"Tatsunori","family":"Shimoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Tsuneizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Akiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiko","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari S.","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"997_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/srep45411","volume":"7","author":"Y Gong","year":"2017","unstructured":"Gong, Y. et al. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci. Rep. 7, 45411 (2017).","journal-title":"Sci. Rep."},{"key":"997_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747\u2013752 (2000).","journal-title":"Nature"},{"key":"997_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1056\/NEJMoa052933","volume":"355","author":"C Fan","year":"2006","unstructured":"Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560\u2013569 (2006).","journal-title":"N. Engl. J. Med."},{"key":"997_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","volume":"28","author":"KD Voduc","year":"2010","unstructured":"Voduc, K. D. et al. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28, 1684\u20131691 (2010).","journal-title":"J. Clin. Oncol."},{"key":"997_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","volume":"141","author":"DJ Lobbezoo","year":"2013","unstructured":"Lobbezoo, D. J. et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res. Treat. 141, 507\u2013514 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"997_CR6","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28, 3271\u20133277 (2010).","journal-title":"J. Clin. Oncol."},{"key":"997_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10549-015-3341-3","volume":"150","author":"K Kast","year":"2015","unstructured":"Kast, K. et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res. Treat. 150, 621\u2013629 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"997_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab govitecan in metastatic Triple-Negative Breast Cancer. N. Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N. Engl. J. Med."},{"key":"997_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"997_CR10","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275\u20131281 (2008).","journal-title":"J. Clin. Oncol."},{"key":"997_CR11","doi-asserted-by":"crossref","unstructured":"Grinda, T. et al. Evolution of overall survival and receipt of new therapies by subtype among 20446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open 6, 100114 (2021).","DOI":"10.1016\/j.esmoop.2021.100114"},{"key":"997_CR12","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"997_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44\u201359 (2020).","journal-title":"Lancet Oncol."},{"key":"997_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32, 983\u2013993 (2021).","journal-title":"Ann. Oncol."},{"key":"997_CR15","unstructured":"European Medicines Agency (E. M. A.). TECENTRIQ\u00ae (atezolizumab). Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf (2021)."},{"key":"997_CR16","unstructured":"Food and Drug Administration (FDA). TECENTRIQ\u00ae (atezolizumab). Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761034s053lbl.pdf (2021)."},{"key":"997_CR17","doi-asserted-by":"crossref","unstructured":"Gennari, A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u20131495 (2021).","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"997_CR18","unstructured":"Chugai Pharmaceutical Co. Ltd. Chugai Obtains Approval for Additional Indication and Formulation for Tecentriq in PD-L1-Positive Triple Negative Breast Cancer. Available at: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20190920153002_648.html (2026)."},{"key":"997_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","volume":"30","author":"M Terada","year":"2023","unstructured":"Terada, M. et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer 30, 872\u2013884 (2023).","journal-title":"Breast Cancer"},{"key":"997_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-024-07273-2","volume":"206","author":"T Kimura","year":"2024","unstructured":"Kimura, T. et al. Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database. Breast Cancer Res. Treat. 206, 91\u2013103 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"997_CR21","unstructured":"NCT02425891. A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130), https:\/\/clinicaltrials.gov\/study\/NCT02425891?cond=NCT02425891&rank=1 (2025)."},{"key":"997_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. & Shakir, S. A. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 29, 385\u2013396 (2006).","journal-title":"Drug Saf."},{"key":"997_CR23","doi-asserted-by":"publisher","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo, J. et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J. Immunother. Cancer 11, e006398 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"997_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2019.1552255","volume":"28","author":"A-S Heimes","year":"2019","unstructured":"Heimes, A.-S. & Schmidt, M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin. Investig. Drugs 28, 1\u20135 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"997_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat, S. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann. Oncol. 27, 559\u2013574 (2016).","journal-title":"Ann. Oncol."},{"key":"997_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jgo.2016.05.007","volume":"7","author":"C Helissey","year":"2016","unstructured":"Helissey, C., Vicier, C. & Champiat, S. The development of immunotherapy in older adults: New treatments, new toxicities?. J. Geriatr. Oncol. 7, 325\u2013333 (2016).","journal-title":"J. Geriatr. Oncol."},{"key":"997_CR27","volume":"4","author":"S Miura","year":"2023","unstructured":"Miura, S. et al. Effectiveness and safety of atezolizumab monotherapy in previously treated Japanese patients with unresectable advanced or recurrent NSCLC: a multicenter, prospective, observational study (J-TAIL). JTO Clin. Res Rep. 4, 100484 (2023).","journal-title":"JTO Clin. Res Rep."},{"key":"997_CR28","volume":"6","author":"E Miyauchi","year":"2025","unstructured":"Miyauchi, E. et al. J-TAIL-2: A prospective, observational study of atezolizumab combined with carboplatin and etoposide in patients with extensive-stage SCLC in Japan. JTO Clin. Res. Rep. 6, 100783 (2025).","journal-title":"JTO Clin. Res. Rep."},{"key":"997_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos, F. X. et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur. J. Cancer 91, 21\u201329 (2018).","journal-title":"Eur. J. Cancer"},{"key":"997_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00579-2","volume":"9","author":"A Fabi","year":"2023","unstructured":"Fabi, A. et al. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. NPJ Breast Cancer 9, 73 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"997_CR31","doi-asserted-by":"crossref","unstructured":"Delaloge, S. et al. LBA3 Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab (atezo) plus nab-paclitaxel (nPac) therapy for patients (pts) with PD-L1+ advanced triple-negative breast cancer (aTNBC). ESMO Open 10, 105114 (2025).","DOI":"10.1016\/j.esmoop.2025.105114"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00997-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00997-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00997-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:10:51Z","timestamp":1792123851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00997-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00997-y","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors received research funding in the form of third-party medical writing assistance from Chugai Pharmaceutical Co., Ltd. T.S.: Lecture fees from Chugai Pharmaceutical Co., Ltd. N.S.: Consulting fees for advisory board participation from Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd.; honoraria from Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Merck Biopharma Co., Ltd., and Bristol Myers Squibb K.K.; and research funding (to institution) from Daiichi Sankyo Co., Ltd., MSD K.K. and AstraZeneca K.K. M.K.: Competing interests from Chugai Pharmaceutical Co., Ltd., AstraZeneca, Pfizer, Eli Lilly and Company, Exact Sciences and Daiichi Sankyo Company. M.T.: Lecture fees from Chugai Pharmaceutical Co., Ltd. M.Yamamoto: Payment or honoraria from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, MSD and Pfizer. Y.O.: Honoraria from Chugai Pharmaceutical Co., Ltd., Pfizer, Eli Lilly and Daiichi Sankyo. Y.O. is the PI of the JBCRG-M10 trial. S.A.: Honoraria from Chugai, Eisai, Eli Lilly, Pfizer, Kyowa Kirin, lshiyaku Publishers, Inc., Nankodo Co., Ltd. and Medical View Co., Ltd. N.H.: Honoraria for lectures from Chugai Pharmaceutical Co., Ltd. M.Y.: Speaker\u2019s fee from MSD, KYOWA KIRIN, Eli Lilly, Gilead Sciences, Chugai Pharmaceutical Co., Ltd., Pfizer, Daiichi Sankyo, Eisai and Exact Sciences. Y.Yamamoto: Research grant and honoraria from Chugai Pharmaceutical Co., Ltd. Member of the Board of Directors of the Japanese Breast Cancer Society and the Japan Breast Cancer Research Group. N.M.: Honoraria (e.g. lecture fees) from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, MSD and Pfizer; Research funding (to institution) from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, MSD, Novartis, Ono-Pharma and Pfizer. Board of directors: Japanese Breast Cancer Society (JBCS; 2021\u20132024), Japan Society of Clinical Oncology (JSCO; 2023\u20132025), Japan Association of Breast Cancer Screening (JABCS2024), Japan Breast Cancer Research Group Association (JBCRG) and Kyoto Breast Cancer Research Network (KBCRN). H.T.: Honoraria for lectures from Chugai Pharmaceutical Co., Ltd., Pfizer, Eli Lilly and Daiichi Sankyo. T.Y.: Honoraria for lectures from AstraZeneca, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Kyowa Kirin, Pfizer and Taiho; consulting\/advisory fees from Daiichi Sankyo, Eli Lilly and Pfizer. Y.K.: Honoraria for lectures from Eisai, Chugai Pharmaceutical Co., Ltd., Pfizer, Eli Lilly, Taiho, Gilead, Exact Sciences and Daiichi Sankyo. T.Taira: Honoraria from Daiichi Sankyo, MSD, Chugai Pharmaceutical Co., Ltd., Eli Lilly, Taiho and Pfizer. S.N., T.Takahashi: Employees of and own stock in Chugai Pharmaceutical Co., Ltd. M.S.O.: Participant honorarium for attending a meeting related to this research from Chugai Pharmaceutical Co., Ltd. N.N.: Payment or honoraria from Chugai Pharmaceutical Co., Ltd., Eli Lilly, MSD, Daiichi Sankyo, AstraZeneca and Pfizer; grants or contracts from Chugai Pharmaceutical Co., Ltd., Pfizer, Eisai and Daiichi Sankyo.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"135"}}